Interpharma, Quintiles and Temasek to Form Pharma Commercialization Joint Venture in Asia Pacific With US$112 Million Investment Fund

HONG KONG and SINGAPORE and RESEARCH TRIANGLE PARK, N.C., June 9

Jun 09, 2005, 01:00 ET from Quintiles Transnational Corp.

/PRNewswire-FirstCall/ -- Three global companies have announced a joint
 venture to commercialize pharmaceutical products in the Asia Pacific region.
 Partners in the joint venture, which will have an investment fund totaling
 US$112 million, include leading Asia Pacific pharmaceutical services group,
 Interpharma Asia Pacific, parent of drug distributor Zuellig Pharma; Asia
 investment company Temasek Holdings (Private) Limited; and Quintiles
 Transnational Corp., the world's leading pharmaceutical services organization,
 who has signed a letter of intent to join the venture. Each partner is
 expected to make an equal investment in the joint venture and own one-third
 each of the company.
     The joint venture will draw on each partner's wide market knowledge,
 experience and success in both the Asia Pacific and global healthcare markets
 to acquire existing and new pharmaceutical products from research-based drug
 companies targeted at the needs of the Asia Pacific region. This service helps
 drug companies focus their resources on R&D and provides outsourcing for
 product registration and sales and marketing of their mature brand portfolios.
     PharmaLink, the specialist Asia Pacific pharmaceutical marketing services
 division of Interpharma, will be transferred to the new JV and will help
 negotiate the acquisition of these products and their subsequent marketing in
 the Asia Pacific healthcare market. Zuellig Pharma will provide distribution
 and logistics expertise. Quintiles will contribute regional commercialization
 expertise and experience in pharmaceutical outsourcing partnerships.
     Mr Fritz Horlacher, Chief Executive of Interpharma said, "Interpharma has
 been in Asia Pacific for more than 60 years and operates in 13 countries in
 the region. We believe that we will be able to actively apply our experience
 and knowledge of local Asian markets. We are pleased to partner with Temasek
 and Quintiles in this venture as we all share a common vision of the exciting
 growth opportunities in the Asia Pacific healthcare environment."
     Dr Dennis Gillings, CBE, Chairman and Chief Executive Officer of Quintiles
 Transnational said, "The joint venture can provide flexible solutions for
 pharmaceutical customers in the Asia Pacific region in managing their product
 portfolios. Quintiles' global clinical knowledge aids in portfolio evaluation
 and our experience in commercialization and pharmaceutical partnerships
 complements well the capabilities of our JV partners. Together, we are a
 commercialization powerhouse."
     Mr S Iswaran, Managing Director, Strategic Development of Temasek Holdings
 said, "Temasek has invested in several biotech and pharma ventures globally.
 This investment fits in well with our view of growth prospects for Asia and
 our overall investment strategy for the life sciences. We are pleased to
 partner with Interpharma and Quintiles, whose knowledge, networks and
 experience in Asia Pacific will be valuable to the success of this joint
 venture."
     According to a leading source of pharmaceutical market intelligence, the
 Asia Pacific pharma market, currently estimated to be US$21 billion, has more
 than doubled over the last 10 years and is projected to double again over the
 next 10 years.
     The joint venture will be managed by a professional team led by Mr Brian
 Nichols, Chief Executive of PharmaLink, who has more than 30 years' experience
 in the pharmaceutical industry in Asia Pacific. Formation of the three-way
 joint venture is subject to the execution of definitive agreements, which is
 expected to occur in a few months.
 
     About Interpharma
     Interpharma Asia Pacific is a pan-regional enterprise operating various
 business units across Asia including Pharma Industries, Zuellig Pharma and
 PharmaLink. These business units provide services to the multi-national R&D-
 based pharmaceutical manufacturers. Please visit www.zuelligpharma.com/ip
     Pharma Industries is a leading provider of contract pharmaceutical
 manufacturing services in the Asia Pacific region. It provides product
 development, planning & procurement and commercial manufacturing services.
 Please visit http://www.pharmaindustries.com
     Zuellig Pharma, the distribution and logistics division of Interpharma, is
 Asia Pacific's leading provider of cutting-edge logistics services covering
 inventory management, warehousing, distribution and customer order management.
 Please visit http://www.zuelligpharma.com
     PharmaLink, the specialist marketing services division of Interpharma Asia
 Pacific, offers the complete marketing solution in Asia Pacific. With
 expertise in orphan drug management, regulatory affairs and sales and
 marketing teams, PharmaLink is Asia's leading sales and marketing
 organization, being the ideal healthcare marketing partner, providing a
 complete range of marketing services and support solutions that are attracting
 more pharmaceutical companies, seeking to increase their growth or expand
 operations into Asia Pacific. PharmaLink has established a reputation for
 sales and marketing excellence with over 1,600 sales representatives marketing
 products in over 19 therapeutic areas.
     For more information, please visit: http://www.pharmaLink.com
 
     About Quintiles Transnational
     Quintiles Transnational Corp. helps improve healthcare worldwide by
 providing a broad range of professional services, information and partnering
 solutions to the pharmaceutical, biotechnology and healthcare industries.
 Headquartered near Research Triangle Park, N.C., USA, Quintiles has offices in
 50 countries and is the world's leading pharmaceutical services organization.
     For more information, visit the company's website
 at http://www.quintiles.com
 
     Information in this press release contains "forward-looking statements."
 These statements involve risks and uncertainties that could cause actual
 results to differ materially, including, without limitation, the risk that the
 parties might not reach final agreement as planned and the joint venture might
 not commence operations as planned or at all.  Additional factors that could
 cause actual results to differ materially are discussed in Quintiles' recent
 filings with the Securities and Exchange Commission, including but not limited
 to its annual report on Form 10-K, its quarterly report on Form 10-Q and its
 current reports on Form 8-K.
 
     About Temasek Holdings
     Temasek Holdings is an Asia investment company headquartered in Singapore.
 It is committed to maximizing long-term shareholder value as an active
 investor and shareholder of successful enterprises.
     Established in 1974, it manages a diversified global portfolio of US$54
 billion, spanning Singapore, Asia and the OECD economies. Its investments are
 in a range of industries: telecommunications and media, financial services,
 property, transportation and logistics, energy and resources, infrastructure,
 engineering and technology, as well as pharmaceuticals and biosciences.
     Singapore-based Temasek-linked companies include well-known listed firms
 such as Singapore Airlines, SingTel, DBS Bank, SMRT Corporation and Neptune
 Orient Lines. Its overseas investments include ICICI Bank, Matrix Laboratories
 and the Apollo Hospital group in India, Bank Danamon and Bank Internasional
 Indonesia in Indonesia, Quintiles Transnational Corp in the US, as well as
 Telekom Malaysia.
     For more information, please visit: http://www.temasekholdings.com.sg
 
 

SOURCE Quintiles Transnational Corp.
/PRNewswire-FirstCall/ -- Three global companies have announced a joint
 venture to commercialize pharmaceutical products in the Asia Pacific region.
 Partners in the joint venture, which will have an investment fund totaling
 US$112 million, include leading Asia Pacific pharmaceutical services group,
 Interpharma Asia Pacific, parent of drug distributor Zuellig Pharma; Asia
 investment company Temasek Holdings (Private) Limited; and Quintiles
 Transnational Corp., the world's leading pharmaceutical services organization,
 who has signed a letter of intent to join the venture. Each partner is
 expected to make an equal investment in the joint venture and own one-third
 each of the company.
     The joint venture will draw on each partner's wide market knowledge,
 experience and success in both the Asia Pacific and global healthcare markets
 to acquire existing and new pharmaceutical products from research-based drug
 companies targeted at the needs of the Asia Pacific region. This service helps
 drug companies focus their resources on R&D and provides outsourcing for
 product registration and sales and marketing of their mature brand portfolios.
     PharmaLink, the specialist Asia Pacific pharmaceutical marketing services
 division of Interpharma, will be transferred to the new JV and will help
 negotiate the acquisition of these products and their subsequent marketing in
 the Asia Pacific healthcare market. Zuellig Pharma will provide distribution
 and logistics expertise. Quintiles will contribute regional commercialization
 expertise and experience in pharmaceutical outsourcing partnerships.
     Mr Fritz Horlacher, Chief Executive of Interpharma said, "Interpharma has
 been in Asia Pacific for more than 60 years and operates in 13 countries in
 the region. We believe that we will be able to actively apply our experience
 and knowledge of local Asian markets. We are pleased to partner with Temasek
 and Quintiles in this venture as we all share a common vision of the exciting
 growth opportunities in the Asia Pacific healthcare environment."
     Dr Dennis Gillings, CBE, Chairman and Chief Executive Officer of Quintiles
 Transnational said, "The joint venture can provide flexible solutions for
 pharmaceutical customers in the Asia Pacific region in managing their product
 portfolios. Quintiles' global clinical knowledge aids in portfolio evaluation
 and our experience in commercialization and pharmaceutical partnerships
 complements well the capabilities of our JV partners. Together, we are a
 commercialization powerhouse."
     Mr S Iswaran, Managing Director, Strategic Development of Temasek Holdings
 said, "Temasek has invested in several biotech and pharma ventures globally.
 This investment fits in well with our view of growth prospects for Asia and
 our overall investment strategy for the life sciences. We are pleased to
 partner with Interpharma and Quintiles, whose knowledge, networks and
 experience in Asia Pacific will be valuable to the success of this joint
 venture."
     According to a leading source of pharmaceutical market intelligence, the
 Asia Pacific pharma market, currently estimated to be US$21 billion, has more
 than doubled over the last 10 years and is projected to double again over the
 next 10 years.
     The joint venture will be managed by a professional team led by Mr Brian
 Nichols, Chief Executive of PharmaLink, who has more than 30 years' experience
 in the pharmaceutical industry in Asia Pacific. Formation of the three-way
 joint venture is subject to the execution of definitive agreements, which is
 expected to occur in a few months.
 
     About Interpharma
     Interpharma Asia Pacific is a pan-regional enterprise operating various
 business units across Asia including Pharma Industries, Zuellig Pharma and
 PharmaLink. These business units provide services to the multi-national R&D-
 based pharmaceutical manufacturers. Please visit www.zuelligpharma.com/ip
     Pharma Industries is a leading provider of contract pharmaceutical
 manufacturing services in the Asia Pacific region. It provides product
 development, planning & procurement and commercial manufacturing services.
 Please visit http://www.pharmaindustries.com
     Zuellig Pharma, the distribution and logistics division of Interpharma, is
 Asia Pacific's leading provider of cutting-edge logistics services covering
 inventory management, warehousing, distribution and customer order management.
 Please visit http://www.zuelligpharma.com
     PharmaLink, the specialist marketing services division of Interpharma Asia
 Pacific, offers the complete marketing solution in Asia Pacific. With
 expertise in orphan drug management, regulatory affairs and sales and
 marketing teams, PharmaLink is Asia's leading sales and marketing
 organization, being the ideal healthcare marketing partner, providing a
 complete range of marketing services and support solutions that are attracting
 more pharmaceutical companies, seeking to increase their growth or expand
 operations into Asia Pacific. PharmaLink has established a reputation for
 sales and marketing excellence with over 1,600 sales representatives marketing
 products in over 19 therapeutic areas.
     For more information, please visit: http://www.pharmaLink.com
 
     About Quintiles Transnational
     Quintiles Transnational Corp. helps improve healthcare worldwide by
 providing a broad range of professional services, information and partnering
 solutions to the pharmaceutical, biotechnology and healthcare industries.
 Headquartered near Research Triangle Park, N.C., USA, Quintiles has offices in
 50 countries and is the world's leading pharmaceutical services organization.
     For more information, visit the company's website
 at http://www.quintiles.com
 
     Information in this press release contains "forward-looking statements."
 These statements involve risks and uncertainties that could cause actual
 results to differ materially, including, without limitation, the risk that the
 parties might not reach final agreement as planned and the joint venture might
 not commence operations as planned or at all.  Additional factors that could
 cause actual results to differ materially are discussed in Quintiles' recent
 filings with the Securities and Exchange Commission, including but not limited
 to its annual report on Form 10-K, its quarterly report on Form 10-Q and its
 current reports on Form 8-K.
 
     About Temasek Holdings
     Temasek Holdings is an Asia investment company headquartered in Singapore.
 It is committed to maximizing long-term shareholder value as an active
 investor and shareholder of successful enterprises.
     Established in 1974, it manages a diversified global portfolio of US$54
 billion, spanning Singapore, Asia and the OECD economies. Its investments are
 in a range of industries: telecommunications and media, financial services,
 property, transportation and logistics, energy and resources, infrastructure,
 engineering and technology, as well as pharmaceuticals and biosciences.
     Singapore-based Temasek-linked companies include well-known listed firms
 such as Singapore Airlines, SingTel, DBS Bank, SMRT Corporation and Neptune
 Orient Lines. Its overseas investments include ICICI Bank, Matrix Laboratories
 and the Apollo Hospital group in India, Bank Danamon and Bank Internasional
 Indonesia in Indonesia, Quintiles Transnational Corp in the US, as well as
 Telekom Malaysia.
     For more information, please visit: http://www.temasekholdings.com.sg
 
 SOURCE  Quintiles Transnational Corp.